Xarator

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xarator

Property Description
Active ingredient Atorvastatin
Form Film-coated oral tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Lipid regulation / Cholesterol management
Origin Synthetic compound

Xarator: Definition and Pharmacological Class

Xarator is a prescription medication containing the active ingredient Atorvastatin, which is classified as an HMG-CoA reductase inhibitor, a group commonly known as statins. This classification identifies the drug as a powerful synthetic agent used for lipid-lowering purposes, specifically by targeting the processes that manufacture cholesterol in the body. Unlike older lipid-lowering therapies, the statin class, including Atorvastatin, is clinically recognized for its ability to produce significant and sustained reductions in circulating cholesterol.

The development of Atorvastatin represents a key advancement in cardiovascular medicine. Statins are central to the therapeutic management of dyslipidemias. This class of medicine is a primary tool for patients requiring assistance in correcting abnormal blood fat levels, such as those with persistently high cholesterol despite dietary adjustments.

Composition, Physical Form, and Therapeutic Purpose

The drug Xarator is a single-component product typically administered via the oral route as a film-coated tablet, ensuring the consistent delivery of the Atorvastatin active substance. The single-ingredient focus allows for predictable targeting of the cholesterol synthesis pathway.

The overall therapeutic purpose of Xarator is to manage and improve the balance of fats, or lipids, circulating in the bloodstream. Through its function, the medicine ultimately contributes to a substantial lowering of harmful low-density lipoprotein cholesterol (LDL-C) and triglycerides, while often yielding a modest increase in beneficial high-density lipoprotein cholesterol (HDL-C). Atorvastatin modulates the overall lipid profile. This regulatory effect is essential for individuals with elevated blood fat levels, as it is integral to supporting long-term vascular and cardiovascular health.

Regulatory References

  1. Statin Medications - StatPearls - NCBI Bookshelf
  2. Atorvastatin: MedlinePlus Drug Information

What side effects are possible with Xarator?

Possible Side Effects and Safety Information

The safety profile of Xarator (Atorvastatin) is documented according to regulatory classifications, detailing observed adverse reactions by incidence and affected physiological system. These classifications range from very common to those of unknown frequency, providing a structured overview of the medicine’s risk profile.

Key adverse reactions are grouped by System-Organ Class (SOC) and frequency, based on official regulatory labeling:


Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common (ge 1/10) Nasopharyngitis
Common (ge 1/100 to < 1/10) Headache, Hyperglycaemia, Gastrointestinal issues (e.g., Diarrhoea), Myalgia, Pain in extremity, Muscle spasms
Rare (ge 1/10,000 to < 1/1,000) Rhabdomyolysis, Peripheral neuropathy, Angioneurotic oedema

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but serious adverse events, including rhabdomyolysis (a severe muscle condition), cases of hepatic failure, and serious skin reactions such as Stevens-Johnson syndrome. Increases in serum transaminases are also observed, though often described as transient.

Safety constraints are explicitly defined for specific populations. The drug is contraindicated for women who are pregnant or breastfeeding, and for individuals with active liver disease or unexplained persistent hepatic transaminase elevations. Furthermore, the label notes an increased risk of muscle effects when used alongside certain medications, such as strong CYP3A4 inhibitors.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Xarator (Atorvastatin) overdose emphasizes the risk of severe systemic manifestations rather than listing a simple acute toxicity profile. The most serious life-threatening outcomes documented in the prescribing information are rhabdomyolysis, a condition involving severe muscle breakdown, and secondary acute renal failure. Other overdose presentations include signs of serious hepatic injury, which may present as jaundice or be detected by clinically significant elevations of liver transaminases and creatine kinase (CK). Increased risk of severe complications exists for the elderly and patients with renal impairment.


Immediate Emergency Actions

Regulatory guidance mandates that patients seek immediate medical attention upon recognizing symptoms suggestive of myopathy or liver injury, such as unexplained muscle pain, dark-colored urine, or yellowing of the skin or eyes. In severe cases involving collapse, seizure, trouble breathing, or unresponsiveness, it is required to immediately call emergency services (911) or the poison control helpline.


Overdose Management

Management of an acute Xarator overdose is defined as symptomatic and supportive. The regulatory text explicitly states that no specific antidote is known for Atorvastatin. Treatment procedures require careful monitoring of the patient, specifically checking serum CK levels and liver function in a clinical setting.

Therapeutic Uses of Xarator

What Xarator Treats: Main Uses and Benefits

Xarator is commonly used to help with the management of two primary therapeutic areas. Firstly, it assists in the reduction of elevated total cholesterol, low-density lipoprotein (LDL-C), and triglycerides in patients with hypercholesterolaemia, including those with genetic forms. This application is an adjunct to diet and is often used in settings marked by temporary physiological imbalance.

Secondly, the medicine supports cardiovascular risk reduction, relevant for easing the risk of major events such as heart attack, stroke, or revascularization procedures in adults at high risk. The overarching benefit is that it helps ease the overall burden of symptoms linked to systemic imbalance.

“Applied across domains where additional symptomatic support is needed.”

This is relevant in clinical scenarios where symptoms escalate temporarily, and where supportive relief is needed to assist with maintaining functional stability.

Quick Fact: Relief for Systemic Imbalance and Functional Strain

Eligibility and Restrictions for Use

Who can and cannot use Xarator?

Eligibility for Xarator (Atorvastatin) is strictly defined by regulatory documents, focusing on patient age, organ function, and reproductive status.

Absolute Contraindications

Use is absolutely contraindicated for patients with:

  • Active liver disease or unexplained persistent elevations of liver enzymes (serum transaminases exceeding three times the upper limit of normal).
  • Known hypersensitivity to atorvastatin or any component of the medication.
  • Pregnancy or while breastfeeding (lactation).
  • Women of child-bearing potential not using adequate contraception.

Population Eligibility and Restrictions

Population Group Regulatory Status
Adults Eligible for standard use.
Children (< 10 years) Use is not indicated.
Pediatrics (≥ 10 years) Eligible only for specific genetic conditions (e.g., Familial Hypercholesterolemia).
Renal Impairment Eligible; generally, no dose adjustment is required.
Hepatic Impairment Use requires caution and monitoring.

Eligibility also requires caution for patients with predisposing factors for muscle toxicity, such as uncontrolled hypothyroidism or a history of muscular disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Xarator (atorvastatin) is subject to several clinically significant interactions, primarily due to its metabolism by the enzyme CYP3A4 and transport by proteins like OATP1B1. These interactions can substantially alter the concentration of Xarator in the body, increasing the risk of muscle-related side effects, including rhabdomyolysis.

Key interaction constraints established by regulatory documents are based on the degree of exposure change:


Contraindicated and High-Risk Combinations

Co-administration is generally contraindicated with potent inhibitors of CYP3A4 and OATP1B1, such as Cyclosporine, and certain anti-viral regimens (e.g., Tipranavir plus Ritonavir, Glecaprevir plus Pibrentasvir). These combinations are prohibited because they dramatically elevate Xarator levels.

Interactions Requiring Dose Limitation

When co-administered with other strong inhibitors, including certain anti-virals (e.g., Lopinavir plus Ritonavir), the antifungal Itraconazole, and the antibiotic Clarithromycin, specific maximum daily doses of Xarator must not be exceeded. This restriction is necessary to maintain Xarator concentrations within a safer range.

Other Significant Interactions

  • Lipid-Lowering Agents: Concomitant use with other lipid-lowering medicines, such as Fibrates or Niacin (ge 1 g/day), carries an increased risk of muscle toxicity and requires careful consideration.
  • Oral Contraceptives and Digoxin: Xarator can increase the blood concentrations of Norethindrone and Ethinyl Estradiol (components of oral contraceptives) and Digoxin, requiring appropriate monitoring by a healthcare provider.

Mechanism of Action

The mechanism of Xarator (Atorvastatin) involves two primary mechanistic domains that lead to physiological modulation. The core action is the competitive inhibition of the enzyme HMG-CoA reductase in the liver . By blocking this rate-limiting step in the mevalonate pathway, the drug restricts the hepatocyte's capacity to synthesize its own cholesterol. The resulting decrease in the intracellular cholesterol pool triggers the up-regulation of LDL Receptors on the cell surface. This increases the liver's ability to actively clear circulating LDL-C from the bloodstream. This cascade leads to changes in systemic lipid concentration. Additionally, through non-lipid actions (pleiotropy), the drug modulates intracellular signal transduction to decrease oxidative stress, which affects the function of the vascular endothelium. This dual action leads to functional changes in lipid regulation and vascular status.

Dosage and Administration Information

How Xarator is Used: Official Administration Guidelines

Xarator is administered orally as a film-coated tablet containing Atorvastatin. The medicine is prescribed as an adjunct to a cholesterol-lowering diet. The tablets are intended to be swallowed whole and can be taken at any time of day, with or without food, which helps maintain the required consistency of the once-daily schedule.


Dosing and Titration

The approved dosage range for adults is between 10 mg and 80 mg once daily. Treatment typically begins with a starting dose of 10 mg or 20 mg. For patients requiring a large reduction in low-density lipoprotein cholesterol, an initial dose of 40 mg is sometimes used. Dosage adjustments, or titration, are systematically performed at intervals of two to four weeks based on an assessment of lipid targets, ensuring a standardized approach to reaching the maintenance dose.


Population and Procedural Rules

For most adults, including older adults and those with renal impairment, no dose adjustment from the standard regimen is required. However, for certain pediatric patients (10–17 years) diagnosed with Heterozygous Familial Hypercholesterolemia, the maximum daily dose is limited to 20 mg. If a dose is missed, it is specified that the patient should skip the missed dose and resume the regular schedule, rather than taking a double dose. It is recommended to avoid the high consumption of grapefruit juice (over 1.2 liters daily) due to potential procedural constraints on the medication's intended action. Therapy with Xarator is generally considered a long-term commitment to maintain the intended effect.

Recent Clinical Evidence

Research evidence / Overview of studies for Xarator

Evidence for Use in Lipid Regulation and Management

Research exploring the study of Xarator in populations with elevated blood lipids, such as cholesterol and triglycerides, primarily relies on Randomized Controlled Trials (RCTs). These studies were generally conducted over short-term to intermediate-term follow-up durations. Researchers were particularly focused on measuring the change in biomarkers like LDL-C (low-density lipoprotein cholesterol) and Total Cholesterol. The populations evaluated were mainly adults with primary hypercholesterolemia, including those with genetic forms.

Within these controlled settings, studies reported the measurement of changes in lipid levels in the observed populations. Research described patterns related to the measurement of shifts in LDL-C and Total Cholesterol biomarkers during the study periods. Data also show patterns related to the measurement of shifts in other lipids, with findings that described changes in triglycerides and HDL-C. Research provides insight into these short-term changes, and systematic reviews contribute to the broader evidence landscape by consolidating these study outcomes.


Evidence for Use in Cardiovascular Event Prevention

The evidence base for research concerning major cardiovascular events was evaluated in large-scale, long-term Randomized Controlled Trials (RCTs) that often lasted several years. Research examined outcomes related to physical discomfort and outcomes reflecting acute changes, such as non-fatal heart attack, stroke, and revascularization procedures. Studies explored this in two primary groups: patients considered high-risk but without established heart disease (primary prevention) and patients with a history of heart issues (secondary prevention).

Studies monitored the rates of these clinical events over defined time intervals. Findings described patterns of differences in the measured incidence rate of these major events between the observed groups, compared to the comparator groups. This evidence contributes to understanding event patterns in populations presenting with cycles of stability and flare-ups related to cardiovascular issues.


Long-Term Follow-Up and Durability of Study Findings

The highest quality evidence related to sustained outcomes was evaluated during the extended observation periods of the major cardiovascular RCTs, where patients were monitored for periods often reaching four to five years. Studies monitored endpoints like recurrent heart attacks and strokes to see how outcomes evolved in the observed populations over these longer terms. Research describes the event patterns observed over the duration of the trial follow-up, but certainty regarding sustained effects beyond this timeframe is limited.

What Is Still Uncertain About Xarator Research

Research provides context but also highlights what is still uncertain about Xarator. One key limitation is that comparative evidence is lacking in certain areas, particularly dedicated head-to-head trials against all currently available alternative therapies for long-term event reduction. Additionally, the core studies primarily focused on hard clinical endpoints and biomarker shifts. Research still needs to more fully characterize the long-term outcomes on patient-centered measures, such as changes in quality of life or overall functional status.

Frequently Asked Questions (FAQ)

Common questions about Xarator (FAQ)

Q: How quickly should a person expect Xarator to start having an effect?

According to official regulatory documents, the medicine starts to enter the bloodstream quickly; maximum concentrations of the active substance occur within 1 to 2 hours of taking the dose. This rapid concentration allows the drug to begin its primary action of inhibiting the cholesterol-producing enzyme.

Q: How long does it typically take to see the full, expected result of Xarator treatment?

While the drug acts quickly, reaching the full, expected result takes time. Dosage adjustments are systematically performed by a healthcare provider at intervals of two to four weeks. These adjustments are based on an assessment of lipid targets, which is done to help identify the appropriate dose.

Q: Can Xarator cause a feeling of unusual tiredness or fatigue?

Yes, fatigue and a lack of strength, known as asthenia, have been reported as side effects. Unusual tiredness or weakness may also be experienced, and official information indicates this can be a symptom accompanying rare, serious muscle problems. Official information suggests discussing any such feelings with your healthcare provider.

Q: Is it normal to feel a bit nauseous or dizzy when first starting Xarator?

Dizziness and nausea (feeling sick) are reported side effects of the medicine. Official patient information advises caution regarding driving or operating machinery if dizziness is experienced.

Q: How long do the initial side effects when starting Xarator usually last?

Patient information suggests that common mild side effects, such as a headache, typically resolve quickly. They are often noted to go away after the first week of treatment. Resolution time frames can vary.

Q: Does Xarator interact with common vitamins or herbal supplements?

The active ingredient in Xarator is subject to clinically significant interactions. Official patient information advises informing your healthcare provider about all herbs, vitamins, or supplements taken, due to the potential for interactions.

Q: Is there a generic version of Xarator available to patients?

Yes, the active ingredient in Xarator, Atorvastatin, is widely available in generic formulations. These generic versions are approved by regulatory bodies, meaning they contain the same active ingredient and meet the same standards for quality and effectiveness.

Q: Does Xarator cause any changes in mood or emotional well-being?

Mental depression is listed in official adverse reaction documents as a possible side effect. The frequency with which this may occur is not known (frequency cannot be estimated from the available data).

Q: Is Xarator a non-habit forming medication?

Yes. Regulatory documents classify the active ingredient in Xarator as a statin, an HMG-CoA reductase inhibitor. It is not classified as a controlled substance or a habit-forming medication.

Q: Has Xarator been approved by health regulatory bodies outside of the United States?

Yes, the medicine is approved and regulated by major international health agencies. This includes the European Medicines Agency (EMA) and other regulatory bodies worldwide.

Q: Can Xarator affect the results of routine blood tests or lab work?

The medicine can affect certain lab results. Specific blood tests for liver function (serum transaminases) are monitored before starting treatment and at specified intervals during treatment, as described in the official label.

Q: Can Xarator be safely crushed, split, or chewed if swallowing pills is difficult?

Official administration guidelines state that the film-coated tablets are intended to be swallowed whole. It is advised to consult with a healthcare provider before altering the form of the medication.

Q: Why are there different colors or shapes of Xarator pills available?

Variations in the color or shape of tablets are common. This often happens between different manufacturers, such as between the brand name and generic versions. However, all formulations must contain the same active ingredient and meet regulatory standards for efficacy and safety.

Q: Is it common to experience dry mouth or changes in appetite while on Xarator?

Loss of appetite is listed as a less common side effect. Dry mouth has also been reported as an oral symptom associated with the use of statins, the class of medicine to which Xarator belongs.

Q: Does Xarator carry a warning about affecting a person's ability to drive or operate machinery?

Official patient information advises caution regarding driving or operating machinery. This is particularly noted because the medicine may cause dizziness in some people.

Q: Are there specific patient monitoring or follow-up tests required when taking Xarator?

Specific monitoring is described in regulatory documents. This includes monitoring liver function with blood tests before starting, and again at 3 months and 12 months after beginning the medication.

Q: What happens if Xarator is taken at an irregular time each day?

The medicine is prescribed to be taken once daily. The regulatory label indicates that the primary effect of reducing low-density lipoprotein cholesterol (LDL-C) is the same regardless of the time of day the dose is administered.

Q: Does Xarator have different effects on men versus women?

The regulatory label states there is no clinically significant difference in the primary LDL-C reduction between men and women. However, some post-marketing reports suggest that women may report certain adverse events at a higher rate.

Q: Is it necessary to inform all doctors, including dentists, that I am taking Xarator?

Yes, patient information leaflets clearly advise informing any other healthcare professionals, including doctors, dentists, and pharmacists who treat you, that you are taking this medicine.

Q: Can lifestyle factors like diet and exercise influence the effect of Xarator?

Yes, lifestyle factors are integral to the treatment plan. The medicine is prescribed as an adjunct to a cholesterol-lowering diet. Regulatory information also lists regular exercise as a helpful self-care measure that can assist with managing cholesterol levels.

How should Xarator be stored and disposed of?

The official regulatory requirements for Xarator (atorvastatin calcium) tablets define strict conditions for storage, protection, and disposal.

Storage and Protection

Item Requirement
Temperature Store at controlled room temperature, typically below 25 C or 30 C.
Protection The tablets must not be frozen and must be protected from light and moisture.
Container Keep the medicine in its original container or blister packaging until use.
Child Safety Keep out of the sight and reach of children as required by regulatory labeling.

Disposal Instructions

Unused or expired Xarator must not be thrown away in household waste or flushed down wastewater. Disposal should follow local regulations, often utilizing dedicated medicine take-back programs or consulting a pharmacist for guidance on proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xarator found in:

A-Z Index: